Bicara Therapeutics received a Buy rating upgrade following encouraging phase 1 clinical trial results for its drug ficerafusp alfa in head and neck cancer, showing promising median overall survival. However, concerns remain about toxicity and the small size of the trial group, so caution is advised until phase 3 pivotal data is available. The company has a strong cash position of $500 million, supporting operations through 2029 and enabling further development and potential commercialization. The key upcoming event is the interim phase 3 trial results expected by mid-2027, which will be critical for valuation and future prospects.
Dogecoin has surged above the $0.10 mark for the first time since early June, supported by a 72% increase in derivatives trading volume and growing open interest reaching $1.66 billion. Spot Dogecoin ETFs in the U.S. saw net inflows of nearly $910,00...
NEAR Protocol has partnered with Ondo Finance to offer tokenized versions of 20 U.S. equities, ETFs, and commodity-backed instruments on the near.com platform. This allows qualified participants to buy and trade shares of major companies like Tesla, ...
Zephyr Energy reported a 45% year-on-year increase in second-quarter production from its non-operated US portfolio, averaging 914 barrels of oil equivalent per day, surpassing management forecasts. Oil made up 69% of production, and strong commodity ...
Solana is advancing its Alpenglow consensus upgrade to the public testnet stage, aiming to reduce transaction finality time from about 13 seconds to roughly 150 milliseconds. This upgrade replaces the current TowerBFT consensus with a new protocol ca...
Zcash surged about 10% to over $1,600, outperforming major cryptocurrencies while Bitcoin stabilized near $87,000 following recent gains. The broader crypto market benefited from declining oil prices and Treasury yields, boosting investor confidence ...
